Why insider trading matters?
If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2022-01-26 | Hagan Joseph P | President and CEO | Buy | 100,000 | $0.22 | $21,520 | Yes |
| 2021-05-17 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 860 | $0.89 | $765 | No |
| 2021-02-16 | Hagan Joseph P | President and CEO | Sell | 4,144 | $1.72 | $7,128 | No |
| 2021-02-16 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 828 | $1.72 | $1,424 | No |
| 2021-02-16 | Hagan Joseph P | President and CEO | Sell | 4,144 | $1.72 | $7,128 | No |
| 2020-12-04 | Walker Paul Edward | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Sonsini Peter W. | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | SANDELL SCOTT D | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | MAKOWER JOSHUA | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Makhzoumi Mohamad | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Florence Anthony A. Jr. | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Chang Carmen | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Behbahani Ali | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | BASKETT FOREST | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-12-04 | Growth Equity Opportunities V, LLC | 10%-Owner | Buy | 4,398,602 | $0.62 | $2,735,930 | Yes |
| 2020-11-16 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 876 | $0.52 | $456 | No |
| 2020-11-16 | Hagan Joseph P | President and CEO | Sell | 6,094 | $0.52 | $3,176 | No |
| 2020-08-14 | Hagan Joseph P | President and CEO | Sell | 4,245 | $0.60 | $2,568 | No |
| 2020-08-14 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 872 | $0.60 | $528 | No |
| 2020-05-15 | Hagan Joseph P | President and CEO | Sell | 4,426 | $0.63 | $2,774 | No |
| 2020-05-15 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 909 | $0.63 | $570 | No |
| 2020-02-18 | Hagan Joseph P | President and CEO | Sell | 4,324 | $0.83 | $3,591 | No |
| 2020-02-18 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 888 | $0.83 | $737 | No |
| 2020-01-02 | Hagan Joseph P | President and CEO | Sell | 8,345 | $0.97 | $8,067 | No |
| 2020-01-02 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 2,239 | $0.97 | $2,164 | No |
| 2019-11-14 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 833 | $0.64 | $533 | No |
| 2019-11-14 | Hagan Joseph P | President and CEO | Sell | 5,838 | $0.64 | $3,736 | No |
| 2019-10-01 | Aker Christopher Ray | Sr. VP & General Counsel | Sell | 2,346 | $0.68 | $1,602 | No |
| 2019-10-01 | Hagan Joseph P | President and CEO | Sell | 8,743 | $0.68 | $5,969 | No |
| 2019-08-15 | Hagan Joseph P | President and CEO | Sell | 4,375 | $0.55 | $2,409 | No |
Insider Smart
Insider Smart